Results from a
clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a
clinical response in 80 percent of
multiple myeloma patients with advanced disease after
undergoing autologous stem cell transplants (ASCT).